METHODS AND RESULTS
We used data from the Medical Expenditure Panel Survey (MEPS), administered by the Agency of Healthcare Research and Quality, for the years 2006 through 2015.
2 Details about the MEPS have been described elsewhere. 1 In brief, the MEPS is a set of large-scale surveys in which data about health service providers and employers are collected on an individual-and family-level designed to provide national estimates. The survey is reported annually, and each observation is assigned weight and variance estimation stratum, based on survey nonresponse and characteristics of the national population for the survey year, following a multi-stage sample design. 2 Because MEPS comprised publicly available, deidentified data files, it was exempt from institutional review board purview. From the MEPS, we used Clinical Classification Software codes to identify all individuals 40 years or older who had ASCVD, incorporating coronary (Clinical Classification Software codes 100 and 101), cerebrovascular (Clinical Classification Software codes 109-113), and peripheral vascular (Clinical Classification Software code 114) disease, or a self-reported history of coronary heart disease, angina, myocardial infarction, or stroke. 1 We categorized financial burden at a family level, following the definition from the Current Population survey of the US Census Bureau.
1 Consistent with prior research, financial burden from OOP expenditures was assessed at the family level, taking into account the effects of sharing costs and income among different members of the same family. 1, 3 Financial burden was defined as the ratio of family annual OOP expenditures to post-subsistence (ie, after food-related expenses) family income. Annual OOP expenses were calculated from the total costs of all healthcare services (incorporating insurance premiums), including expenses for inpatient care, outpatient (or ambulatory) care, emergency medical care, and prescription medications, as well as other health services (home health care and medical equipment) for each year. 2 A ratio from 20% to 40% was defined as high financial burden, whereas a ratio >40% was defined as catastrophic healthcare expenditure.
Healthcare-related quality of life was assessed by means of the physical and mental health component summaries (12-item Short-Form [SF-12] physical component score and SF-12 mental component score, respectively) from the 12-SF Health Survey Version 2. 5 The SF-12 physical component score and the SF-12 mental component score range from 0 to 100, with higher scores indicating better HRQoL. A difference of ≥3 points in SF-12 physical component score or SF-12 mental component score has been deemed as clinically significant. 6 We divided each summary score into quartiles, with the lowest quartile reflecting poor physical/mental health. Self-perception of health was ascertained by self-report, ranging from 1-excellent to 5-poor. We further dichotomized individuals with fair/poor responses about self-perception of health to compare with those with more favorable responses. Nonspecific psychological distress was measured using the Kessler Index, 7 which ranges from 0 to 24; higher values denote higher levels of psychological distress. Given that a cutoff value of ≥13 has been suggested as a reference for screening for mental illness, we categorized the Kessler Index to reflect a high psychological distress if any score resulted in 13 points or higher. 7 Risk of depression was assessed via the Patient Health Questionnaire 2, which has been validated as an initial assessment for depression in the primary care population. 8 Patient Health Questionnaire 2 scores range from 0 to 6, with a higher score implying a greater tendency toward risk for depression, although this is not to be considered a diagnostic tool. 8 Because ≥3 is considered an optimal point for depression screening, we incorporated that threshold to determine patient depression using the Patient Health Questionnaire 2.
All variables were studied both as continuous and categorical variables. All estimates are reported at the personal level. Proportions were used to estimate prevalence, and unadjusted and adjusted linear and logistic regression models were used to describe the association between exposure and outcomes. All analyses took into consideration the MEPS's survey design and were conducted using Stata, version 13.1 (StataCorp, LP, College Station, TX). J. Valero-Elizondo was responsible for all analyses.
The study population included 20 131 individuals, aged ≥40 years, with ASCVD from 2006 to 2015 (weighted: 22.2 million US adults annually), with a mean age of 67.6 years (SD=9.4), and with 47% being women. We found that 16% were part of families with high financial burden and 7.6% were part of families with catastrophic healthcare expenditures (weighted: 3.56 and 1.68 million US adults annually, respectively). Individuals with financial burden from OOP costs were more likely to be older, non-Hispanic white, from a lower family income level, and to have a higher burden of cardiovascular risk factors and comorbidity count ( Table I in the Data Supplement).
We observed a significant trend of lower mean HRQoL measures across worsening financial burden categories (Table) . Individuals with high financial burden and catastrophic health expenditure had a mean SF-12 physical component score of 34.5 and 32.9 (versus 38.0 from those with no financial burden; both P<0.001) and a mean SF-12 mental component score of 46.9 and 44.9 (versus 48.5 from those with no financial burden; P trend <0.001), respectively. These differences remained after adjusting for known confounders and upon stratification of certain population subgroups (Table and  Table II in the Data Supplement, respectively). Accounting for demographics, family income, and disease burden, compared with those without financial burden, adults with ASCVD and high financial burden or catastrophic healthcare expenditure had 1.26 to 1.44 and 1.58 to 2.00 higher odds of poor mental and physical quality of life, respectively (Figure) . Similarly, those with catastrophic health expenditure were more likely to report worse health status (odds ratio, 1.86; 95% CI, 1.65-2.10), high psychological distress (odds ratio, 1.73; 95% CI, 1.43-2.10), and higher risk for depression (odds ratio, 1.55; 95% CI, 1.35-1.79; Figure) . 
DISCUSSION
In this study, we observed that financial burden, particularly the presence of catastrophic health expenditure, is negatively associated with HRQoL, poor perception of health, nonspecific psychological distress, and high risk for depression. This relationship persisted even after adjusting for demographics, family income, insurance status, underlying risk factors, severity and comorbidity burden, as well as among specific population subgroups such as family income (Table II in the Data Supplement), suggesting that the association was not confounded by key patient-level characteristics impacting financial burden severity.
Although the high cost of treatment among cancer patients has been documented to be associated with negative unanticipated consequences including impairment in quality of life, financial distress and heightened risk of depression, [9] [10] [11] [12] to the best of our knowledge, this is the first study to demonstrate association between financial impact of ASCVD on the self-reported quality of life and psychological wellbeing using a wide range of well-validated metrics for these domains. Although the cross-sectional nature of our study precludes causal inference and a precise understanding of the mechanisms that account for these consistent associations, quality of life measures, overall, and psychological wellness have been linked with adherence to medical care, risk of progression of disease, adverse higher readmissions, and mortality among ASCVD patients. 13, 14 Irrespective of directionality of these associations, they are relevant as ascertainment of financial burden captures those potentially at high risk not identified through other metrics. 9 Furthermore, our study contributes to increasing awareness of financial burden as a potential adverse effect of medical care in these patients. These preliminary insights also support future studies to evaluate the impact of interventions such as early identification of those at risk, incorporating disclosure of financial burden of ASCVD treatment in shared management decisions with patients, and early utilization of healthcare/community resources, with the goal of limiting the dire consequences from healthcare costs for these patients and their families.
These findings should be interpreted in light of some limitations. First, the MEPS data are subject to potential recall bias because of its reliance on selfreported responses, and diagnosis of ASCVD was not independently verified with medical records. However, MEPS uses a network of trained interviewers who encourage participants to share objective information-such as medical records, if possible. 2 Second, cost information is frequently compiled by MEPS interviewers with information from bills for various healthcare services availed by participants. Moreover, both our study population with ASCVD and our exposure of cost and family income are based on the approach used by prior studies. 1, 3 In conclusion, this contemporary nationally representative study draws attention to the negative impact of financial burden from healthcare costs on HRQoL, self-perception of health, psychological distress, and depression risk among those with ASCVD. As out-ofpocket cost sharing for these patients continue to rise, future efforts should be expanded to identify pragmatic approaches not only to limit financial toxicity from regular care but also to assess the potential impact on meaningful patient-centric outcomes including quality of life and psychological well-being.
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